From Early 2020 To Q3: Biogen Shifts Aducanumab Filing Expectations Again

 
• By Mandy Jackson

The company remains confident in US FDA approval for the first disease-modifying Alzheimer’s drug based on current data, but Biogen needs more time to complete the BLA filing.

Mobile Electronic Traffic Sign stating “expect Delays” taken at sunset with traffic blurred driving past the sign and traffic cones
Biogen will file its aducanumab BLA in Q3 versus prior guidance of early 2020 • Source: Shutterstock

More from Earnings

More from Business